Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)

Not Applicable

Completed

• Conditions: Central Serous Chorioretinopathy
• Interventions: Device: subthreshold micropulselaser; Drug: bevacizumab

• Registration Number: NCT00802906
• Lead Sponsor: Johann Wolfgang Goethe University Hospital

Brief Summary

The purpose of this study is to evaluate the clinical efficacy of an initial subthreshold retinal micropulselasercoagulation versus a single intravitreal 1.5mg bevacizumab injection in central serous choriretinopathy, as the micropulse will selectively treat the damaged RPE to induce reproliferation of healthy RPE cells, whereas the intravitreal injection should non-selectively stop the RPE leakage.

Detailed Description

To evaluate the clinical efficacy of an initial subthreshold retinal micropulselasercoagulation in twelve eyey per group versus a single intravitreal 1.5mg bevacizumab injection in central serous choriretinopathy, as the micropulse will selectively treat the damaged RPE to induce reproliferation of healthy RPE cells. BCVA in EDTRS score, OCT, and leakage in FLA, static perimetry of both groups will be correlated to a control group without treatment over 10 months.

Study Timeline

• Study Start: 2007-05
• Study First Submitted: 2008-12-04
• Study First Submitted QC: 2008-12-04
• Study First Posted: 2008-12-05
• Primary Completion: 2010-11
• Study Completion: 2010-12
• Status Verified: 2012-09
• Last Update Submitted: 2012-09-26
• Last Update Posted: 2012-09-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Not provided

Exclusion Criteria

• History of macular or chorioretinal inflammation
• Lens / corneal opacities

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	subthreshold micropulselaser	1.5 mg bevacizumab single injection and on demand if leakage is persistent or recurs
2	subthreshold micropulselaser	initial selective subthreshold micropulselasercoagulation and on demand if leakage is persistent or recurs
1	bevacizumab	1.5 mg bevacizumab single injection and on demand if leakage is persistent or recurs

Primary Outcome Measures

Name	Time	Method
BCVA in EDTRS values	24 months

Secondary Outcome Measures

Name	Time	Method
OCT, leakage in FA, defects in satic perimetry	24 months

Trial Locations

Locations (1)

ZAU Department of VR surgery; 🇩🇪 Frankfurt / Main, Hessen, Germany